Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for EBUS-TBNA Sedation
NCT03521505Phase 4Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- May 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexmedetomidine (2 arms), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Hypoxemia During Maintenance up to 120 minutes. Started May 2018; status: completed.
02
Drugs
dexmedetomidine
Beyond the preview
Go deeper on NCT03521505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521505.